Antihypertensives, angiotensin, glucose and Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 13, Issue 5, 2013, Pages 477-482

  Nelson, Lucy ^a   Tabet, Naji ^a   Richardson, Cassie ^a   Gard, Paul ^b  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Alzheimer's disease; angiotensin; antihypertensives; cognition; glucose; hypertension

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIPIZIDE; GLUCOSE; NEUROTRANSMITTER; PLACEBO;

AGE; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BRAIN BLOOD FLOW; COGNITION; DEMENTIA; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDUCATION; HUMAN; HYPERTENSION; INTELLIGENCE QUOTIENT; MEMORY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; VASCULAR AMYLOIDOSIS; WHITE MATTER;

ALZHEIMER DISEASE; ANGIOTENSINS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 84876947036     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.32     Document Type: Review

References (44)

1. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 263-269 (2011)
2. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J. Am. Board Fam. Med. 25(3), 350-366 (2012)
3. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc. Psychiatry Neurol. 2012, 367516 (2012)
4. Waldstein SR, Wendell CR, Lefkowitz DM et al. Interactive relations of blood pressure and age to subclinical cerebrovascular disease. J. Hypertens. 30(12), 2352-2356 (2012)
5. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4(8), 487-499 (2005)
6. Beason-Held LL, Moghekar A, Zonderman AB, Kraut MA, Resnick SM. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 38(6), 1766-1773 (2007)
7. Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI; SMART Study Group. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann. Neurol. 71(6), 825-833 (2012)
8. Schuff N, Matsumoto S, Kimiecik J et al. Cerebral blood flow in ischemic vascular dementia and Alzheimers disease by arterial spin labeling MRI. Alzheimers Dement. 5, 454-462 (2009)
9. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 13(Suppl. 3), S115-S123 (1999)
10. Weller RO, Boche D, Nicholl JA. Microvascular changes and CAA in AD and their potential impact on therapy. Acta Neuropathol. 118(1), 87-102 (2009)
11. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/ lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 62(12), 1287-1301 (2003)
12. Breteler MM. Vascular involvement in cognitive decline and dementia: epidemiological evidence from the Rotterdam study and the Rotterdam scan study. Ann. NY Acad. Sci. 903, 457-465 (2000)
13. Debette S, Seshadri S, Beiser A et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77(5), 461-468 (2011)
14. Petrovitch H, White LR, Izmirilian G et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol. Aging 21(1), 57-62 (2000)
15. Sun X, He G, Qing H et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl Acad. Sci. USA 103(49), 18727-18732 (2006)
16. Zhang X, Zhou K, Wang R et al. Hypoxia-inducible factor 1α (HIF-1α)- mediated hypoxia increases BACE1 expression and β-amyloid generation. J. Biol. Chem. 282(15), 10873-10880 (2007)
17. Gentile MT, Poulet R, Di Pardo A et al. β-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol. Aging 30(2), 222-228 (2009)
18. Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension 45(3), 374-379 (2005)
19. Stern Y. Cognitive reserve. Neuropsychologia 47(10), 2015-2028 (2009)
20. Spieth W. Cardiovascular health status, age, and psychological performance. J. Gerontol. 19, 277-284 (1964)
21. Khachaturian AS, Zandi PP, Lyketsos CG et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63(5), 686-692 (2006)
22. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of antihypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 26(4), 699-708 (2011)
23. Igase M, Kohara K, Miki T. The association between hypertension and dementia in the Elderly. Int. J. Hypertens. 2012, 320648 (2012)
24. Forette F, Seux ML, Staessen JA et al.; Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162(18), 2046-2052 (2002)
25. Itkin A, Dupres V, Dufrêne YF, Bechinger B, Ruysschaert JM, Raussens V. Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS ONE 6(3), e18250 (2011)
26. Hoffman LB, Schmeidler J, Lesser GT et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72(20), 1720-1726 (2009)
27. Tzourio C, Anderson C, Chapman N et al.; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 163(9), 1069-1075 (2003)
28. Fournier A, Oprisiu-Fournier R, Serot JM et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother. 9(9), 1413-1431 (2009)
29. Gard PR, Rusted JM. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev. Neurother. 4(1), 87-96 (2004)
30. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 264(3), 224-236 (2008)
31. Wright JW, Harding JW. Brain renin- angiotensin - a new look at an old system. Prog. Neurobiol. 95(1), 49-67 (2011)
32. Vanderheyden PM. From angiotensin IV binding site to AT4 receptor. Mol. Cell. Endocrinol. 302(2), 159-166 (2009)
33. Stragier B, De Bundel D, Sarre S et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail. Rev. 13(3), 321-337 (2008)
34. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, Type 2 diabetes, and cognitive function. J. Clin. Exp. Neuropsychol. 26(8), 1044-1080 (2004)
35. Ba-Tin L, Strike P, Tabet N. Diabetic peripheral microvascular complications: relationship to cognitive function. Cardiovasc. Psychiatry Neurol. 2011, 723434 (2011)
36. Lindeman RD, Romero LJ, LaRue A et al.; New Mexico Elder Health Survey. A biethnic community survey of cognition in participants with Type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey. Diabetes Care 24(9), 1567-1572 (2001)
37. Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J. Am. Geriatr. Soc. 41(12), 1305-1312 (1993)
38. Hassing LB, Hofer SM, Nilsson SE et al. Comorbid Type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33(4), 355-361 (2004)
39. Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimer's Disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol. Rev. doi:10.1212/ WNL.0b013e3181f4d7f8 (2013) (Epub ahead of print)
40. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277(10), 813-817 (1997)
41. Dore GA, Elias MF, Robbins MA, Elias PK, Nagy Z. Presence of the APOE epsilon4 allele modifies the relationship between Type 2 diabetes and cognitive performance: the Maine-Syracuse Study. Diabetologia 52(12), 2551-2560 (2009)
42. Farmer ME, White LR, Abbott RD et al. Blood pressure and cognitive performance. The Framingham Study. Am. J. Epidemiol. 126(6), 1103-1114 (1987)
43. Obisesan TO, Obisesan OA, Martins S et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J. Am. Geriatr. Soc. 56(3), 501-509 (2008)
44. Rastas S, Pirttilä T, Mattila K et al. Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study. Neurobiol. Aging 31(1), 1-7 (2010)